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Abstract 
In this study, we investigated the feasibility and safety of intravenous transplantation of allo-
geneic bone marrow mesenchymal stem cells (MSCs) for femoral head repair, and observed 
the migration and distribution of MSCs in hosts. MSCs were labeled with green fluorescent 
protein (GFP) in vitro and injected into nude mice via vena caudalis, and the distribution of 
MSCs was d y n a m i c a l l y   m o n i t o r e d   a t   0 ,   6 ,   2 4 ,   4 8 ,   7 2   a n d   9 6   h   a f t e r   t r a n s p l a n t a t i o n .   T w o   w e e k s  
after the establishment of a rabbit model of femoral head necrosis, GFP labeled MSCs were 
injected into these rabbits via ear vein, immunological rejection and graft versus host disease 
were observed and n e c r o t i c   a n d   n o r m a l   f e m o r a l   h e a d s ,   b o n e   m a r r o w s ,   l u n g s ,   a n d   l i v e r s   w e r e  
harvested at 2, 4 and 6 w after transplantation. The sections of these tissues were observed 
under fluorescent microscope. More than 70 % MSCs were successfully labeled with GFP at 
72 h after labeling. MSCs were uniformly distributed in multiple organs and tissues including 
brain, lungs, heart, kidneys, intestine and bilateral hip joints of nude mice. In rabbits, at 6 w 
after intravenous transplantation, GFP labeled MSCs were noted in  the lungs, liver, bone 
marrow and normal and necrotic femoral heads of rabbits, and the number of MSCs in bone 
marrow was higher than that in the, femoral head, liver and lungs. Furthermore, the number 
o f   M S C s p e a k e d   a t   6   w   a f t e r   t r a n s p l a n t a t i o n .  Moreover, no immunological rejection and graft 
versus host disease were found after transplantation in rabbits. Our results revealed intra-
venously implanted MSCs could migrate into the femoral head of hosts, and especially migrate 
directionally and survive in the n e c r o t i c   f e m o r a l   h e a d s .   T h u s ,   i t   i s   f e a s i b l e   a n d   s a f e   t o   t r e a t  
femoral head necrosis by intravenous transplantation of allogeneic MSCs. 
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Introduction 
Recently,  stem  cell  transplantation  has  been  a 
focus  in  the  treatment  of  some  diseases. Stem cells 
have  the  potential  of  multi-directional  differentia-
tions, and t h e y   c a n   d i f ferentiate into specialized cells 
to repair injured tissues under certain conditions [1]. 
Animal  experiments  have  demonstrated  that  in 
anoxic  environment, implanted stem cells can diffe-
rentiate and promote neovascularization which effec-
tively increase the blood perfusion in ischemic tissues, 
and thus inhibit further necrosis of tissues [2,3]. Re-Int. J. Med. Sci. 2011, 8 
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searchers  have  transplanted  the  bone  marrow  stem 
cells into the necrotic femoral heads, and results show 
b o n e   m a r r o w   s t e m   c e l l s   c an remove vascular lesions 
and promote angiogenesis in necrotic femoral heads, 
accompanied  by  significant  improvement  of  blood 
circulation  in  the  necrotic  femoral  head  and  sur-
rounding tissues [4]. Mesenchymal stem cells (MSCs) 
are multipotent stem cells that can differentiate into a 
variety o f   c e l l   t y p e s .   I n   t h e   f i e l d   o f   c e l l   transplantation, 
MSCs  have many advantages over  other  cell  types 
such as easy isolation and culture, rapid in vitro am-
plification, differentiation  potential,  and  easy  collec-
tion  [2].  Currently,  MSCs  have  been  applied  in  the 
treatment  of  femoral  head  necrosis.  Experiments 
demonstrate the  implanted  MSCs  can  not  only  sur-
vive but proliferate in the necrotic femoral head after 
transplantation,  promoting  the  repair  of  injured  fe-
moral head [5]. In addition, intravenously implanted 
MSCs can migrate into and repair the injured tissues 
[6,7].  Thus,  allogeneic  transplantation  of  MSCs 
through  intravenous  injection  may  be  a  minimally 
invasive  strategy  for  the  treatment  of  femoral  head 
necrosis.  In  this  study,  green  fluorescent  protein 
(GFP)  labeled  allogeneic  MSCs  were  intravenously 
injected into nude mice and the distribution and mi-
gration  of  MSCs  were  dynamically  monitored  to 
evaluate the feasibility and safety of intravenous im-
plantation of allogeneic MSCs in the treatment of fe-
moral head necrosis. Our study may provide theoret-
ical basis for the clinical application of MSCs.  
Materials and methods 
Reagents and instruments 
In  the  present  study,  L-DMEM  medium,  fetal 
b o v i n e   s e r u m   ( H y c l o n e ,   U S A ) ,   P e r c o l l   s e p a r a t i n g  
medium (Sigma, USA), Kodak DXS small animal im-
aging  system  and  adenovirus  vector  carrying  GFP 
(Adeasy GFP) were used. The adenovirus vector car-
rying GFP  was  kindly  provided  by  Professor  Zhou 
(Peking University, China). 
Experimental animals 
A total of 12 male rabbits (6 months old) weigh-
ing  2.5  ±  0.5  kg  and  18  nude  mice  (6  weeks  old) 
weighing 15-20 g  were  purchased  from  the  Experi-
m e n t a l   A n i m a l   C e n t e r ,   A c a d e m y   o f   M i l i t a r y   M e d i c a l  
Sciences,  China.  T h i s   s t u d y   w a s   a p p r o v e d   b y   t h e  
Ethics Committee of our university.  
Amplification and purification of Adeno-GFP 
recombinant adenovirus vector  
Adeno-G F P   i n f e c t e d   H E K 2 9 3   c e l l s   a n d   their  ly-
sate  were  harvested when cytopathogenic effects ap-
peared. After three freeze-thaw  cycles, solution was 
centrifuged at 14000 g for 10 min, and  viruses were 
harvested from the  supernatant. Viruses were puri-
fied by cesium chloride density gradient centrifuga-
tion, and virus titer was determined after the forma-
tion  of  virus  negative  colonies.  Virus  vectors  were 
preserved at -80 ºC.  
Isolation, purification, culture and identification 
of rabbit MSCs 
Heparin  anti-coagulated bone marrow was col-
lected from the rabbit right proximal tibia under ste-
rile conditions.  MSCs were isolated by  density  gra-
dient  centrifugation  with  Percoll.  Then,  these  cells 
were  re-suspended  in  L-DMEM  culture  medium 
containing 10% fetal bovine serum, 100 U/ml  strep-
tomycin and 100 U/ml penicillinum a t   a   d e n s i t y   o f  
2.0×105/cm2 and incubated in 25 cm2 flasks at 37 ºC in 
humidified atmosphere with 5% CO2. After 3 days of 
culture, the medium was refreshed, and then the me-
dium c h a n g e d   e v e r y   o t h e r   d a y .   C e l l   p a s s a g ing was 
performed  when  cell  confluence  reached  85%.  The 
purity and immunophenotype of MSCs and their po-
tentials  of  osteogenesis  and  adipogenesis  were  de-
termined.  
Femoral head necrosis animal model 
T h e   r a b b i t   m o d e l   o f   f e m o r a l   h e a d  necrosis  was 
established  according  to  previously  reported  [8]. 
Weight loading area of femoral heads was exposed 
and treated with liquid nitrogen for 3-5 min until the 
articular cartilage of femoral head became pale.  Im-
mediately, femoral head was re-warmed with normal 
saline at 37 ºC for 3 min. Then, the wound was closed 
and covered with sterile dressing, and 800 000 U  of 
penicillin were intramuscularly administered for each 
rabbit immediately followed by 400 000 U   o f  penicillin 
daily for consecutive 5 days. 
Cell labeling and transplantation  
I n   o r d e r   t o   o b s e r v e   t h e   d i s t r i b u t i o n   o f   i m p l a n t e d  
MSCs in vivo, MSCs were labeled with GFP in  vitro 
before transplantation [9].  In brief, the solution con-
t a i n i n g   G F P   w a s   a d d e d   t o   M S C s   f o l l o w e d   b y   i n c u b a-
tion for 6 h. Then, low glucose DMEM containing 10% 
s e r u m   o f   e q u a l   v o l u m e   w a s   a d d e d   f o l l o w e d   b y   i n c u-
bation  for  72  h.  The  transfection  efficiency  was  de-
tected  under  a  fluorescence  microscope.   A   t o tal  of 
5×105 GFP-labeled MSCs   ( a b o u t   i n   3 0 0   μl of cell sus-
pension) were injected into nude mice through vena 
caudalis. At 0, 6, 24, 48, 72 and 96 h after transplanta-
tion, the nude mice were anesthetized and placed in a 
supine position. The in vivo GFP-labeled MSCs  were 
dynamically monitored in a K o d a k   D X S   s m a l l  animal 
imaging  system  [10].  When,  the  anesthetized  nude 
mice  were  placed  on  the  platform,  the  background Int. J. Med. Sci. 2011, 8 
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i m a g e   w a s   t a k e n   u n d e r   t h e   l i g h t s   o f   a n   i l l u m i n a t o r .  
Then, the illuminator was turned off, and t h e   i m a g e  of 
light emitted from the nude mice, namely biolumi-
nescence image, was taken. Then, two images were 
merged and t h e   l o c a t i o n   o f   l i g h t   s o u r c e   was shown in 
mice.  
At  2  w  after  femoral  head  necrosis,  5×107 
GFP-labeled  MSCs   ( a b o u t   i n   3   m l   o f   c e l l   solution) 
were injected into rabbits through the ear vein, within 
more than 1 min. Necrotic and normal femoral heads, 
bone marrows, lungs and livers were harvested at 2, 4 
and 6 w after transplantation and sectioned followed 
by observation under a fluorescent microscope. At 24 
h ,   7 2   h ,   1   w ,   4   w   a n d   6  w after transplantation, the 
manifestations of immunological rejection and graft 
versus host disease were monitored. 
Statistical analysis  
Three sections were used for analysis. Five fields 
from  each  section were randomly selected and GFP 
positive cells were counted at a magnification of 200. 
Data were expressed as means ± standard deviation 
(SD). Statistical analysis was performed with SAS6.12 
statistic software package and Student t test was car-
ried out for comparisons. A   v a l u e   o f   P<0.05 was con-
sidered statistically significant. 
Results 
Observation of immunological rejection and 
graft versus host disease 
During  the  experiment,  all  animals  survived. 
There were no significant changes in the  heart rate, 
breath rate,   b o d y   t e m p e r a t u r e ,   m e n t a l   c o n d i t i o n ,   u r i-
nation, and  defecation. Routine  blood tests and tests 
of l i v e r   o r   r e n a l   f u n c t i o n s   s h o w e d   n o r m a l .   N o   a c u t e   o r  
chronic  toxicity  and  manifestations  of  graft  versus 
host disease were observed. Besides, no swelling at 
injection  sites  and  lower  limb  movement  disorder 
were noted.  
Isolation,   culture, identification and GFP labeling 
of MSCs 
At  early  stage,  rabbit  MSCs  were  long  spin-
dle-shaped  and  fibroblast-like,  and  arranged  paral-
lelly.   S u b s e q u e n t l y ,   a   m a j o r i t y   o f   MSCs  gradually 
presented whirl-like growth (Figure 1A), and a small 
a m o u n t   o f   r a b b i t   M S C s were polygonal. After Ade-
no-GFP infection, the morphology, and proliferation 
of  cells  were not  significantly changed (Figure 2). At 
24 h after infection, scattered green fluorescence was 
observed under fluorescence microscope and  bright 
green  fluorescent  observed  at  72  h  after  infection 
(Figure 1B). The infection rate was over 70%.  
F l o w   c y t o m e t r y   s h o w e d   t h e   M S C s   h a d   n o   e x-
pressions of CD34, CD45 and HLA-DR,   b u t   h i g h   e x-
pressions of CD29 and CD44. Furthermore, the purity 
o f   c e l l s   w i t h   t h e s e   p h e n o t y p e s   w a s   a s   h i g h   a s   9 9 %  
which suggested the homogeneous phenotype. After 
adipogenesis induction for 1 week, oil red O staining 
showed lipid droplets in the MSCs. After osteogenesis 
induction  for  1  week,  alkaline phosphatase staining 
showed positive cells, and 3 weeks after osteogenesis 
induction, bone nodule was present demonstrated by 
VonKossa staining (Figure 3 A, B, C).  
 
 
 
F i g u r e   1  MSCs after isolated culture.   a :   M S C s of passage 3 under a light microscope (×100) ;   b :   M S C s   l a b e l e d   w i t h   GFP under 
fluorescent microscope(×100). Int. J. Med. Sci. 2011, 8 
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F i g u r e  2 Cell proliferation curve. The proliferation of Adeno-GFP infected MSCs was similar to that of normal MSCs.  
 
F i g u r e   3  Induction of osteogenesis and adipogenesis of MSCs  (×100).  A: One week after osteogenesis induction, alkaline 
phosphatase staining showed positive cells. B: One week after adipogenesis induction, oil red O staining showed lipid droplets 
in the MSCs. C: Three weeks after osteogenesis induction, bone nodule was present demonstrated by VonKossa staining. 
 
Distribution of MSCs in vivo 
Kodak DXS small  animal imaging system is a 
real-time imaging system which can b e   u s e d   t o   ob-
serve the distribution of cells in living animals in a 
real time pattern.   I n   t h e   i m a g i n g   s y s t e m ,   G F P   f l u o-
rescence  presented  bright  white.  Most  implanted 
MSCs  c o n c e n t r a t e d   i n   t h e   t a i l   o f   n u d e   m i c e   imme-
diately after  transplantation, and a  small  amount  of 
MSCs were distributed in the right hip joint. Subse-
quently,  MSCs migrated into  almost all organs,  and 
were uniformly distributed in the brain, lungs, heart, 
kidney, intestine, hip joints and other organs at 24  h 
after transplantation. At 48 h after transplantation, the 
amount  of  MSCs in tissues gradually decreased, and 
n e a r l y   n o   G F P   f l u o r e s c e n c e   w a s   o b s e r v e d   i n   n u d e  
mice at 96 h after transplantation. These findings in-
dicate that intravenously injected MSC could migrate 
into the femoral head and stayed in the femoral head 
for a relatively long time (Figure 4 A-F). 
Gross presentations of femoral head 
T h e   s u r f a c e   o f   n o r m a l   f e m o r a l   h e a d   w a s   s m o o t h  
and round, and the articular cartilage was transparent 
and glossy (Figure  5A). After surgery, the shape of 
femoral  head  was  not  markedly  changed  and  the 
surface of femoral head was pale and dull without 
normal glossiness and smoothness. The transparency 
was  decreased ( F i g u r e   5 B ) .   A t   6   w   a f t e r   M S C   t r a n s-
p l a n t a t i o n ,   t h e   s h a p e   o f   f e m o r a l   h e a d   w a s   integrity 
and the articular cartilage largely preserved. The ar-
ticular cartilage was  glossy and smooth, a fraction of 
which present dark red (Figure 5C).  
Distribution of GFP positive cells in nude mice  
After  blue  excitation  light  was  absorbed,  GFP 
presented green fluorescence. At 6 h after intravenous 
allogeneic  MSC  implantation,  GFP-labeled  MSCs 
were observed in  the l u n g s ,   l i v e r ,   b o n e   m a r r o w   a n d  
normal femoral head, and the amount of GFP positive 
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MSCs in the bone marrow was higher than that in the 
liver, lungs and femoral head. There were also a lot of 
GFP labeled MSCs in  the necrotic region of  femoral 
head at different time points, and the number of cells 
presenting  green  fluorescence  reached  a  maximal 
level  at  6  w  after  transplantation,  indicating  that 
intravenously  implanted  GFP-labeled  MSCs can mi-
grate  into  multiple tissues with circulation of blood 
flow. MSCs could directionally migrate into and sur-
vive in the necrotic area of femoral heads (Table 1 and 
Figure 6).  
 
 
Figure 4. In vivo migration o f   M S C s after transplantation. A: immediately after intravenous MSCs transplantation; B:   6   h   a f t e r  
MSCs transplantation; C: 24 h after MSCs transplantation; D:   4 8   h   a f t e r   MSCs transplantation; E: 72 h after MSCs trans-
plantation; F: 96 h after MSCs transplantation. 
 
 
F i g u r e   5  Gross presentations of normal and necrotic femoral heads.   A: Femoral head before necrosis; B: Femoral head 
i m m e d i a t e l y   a f t e r   n e c r o s i s ;   C :   F e m o r a l   h e a d   a t   6   w   a f t e r   MSCs transplantation. Black arrow shows the surface of femoral 
h e a d .   T h e   n o r m a l   f e m o r a l   h e a d   w a s   smooth and round, and the articular cartilage was transparent and glossy (A). After 
f r e e z i n g ,  t h e   f e m o r a l   h e a d   w a s   p a l e   i n   t h e   a b s e n c e   o f   normal glossiness and smoothness ( B ) . A   f r a c t i o n   o f   articular cartilage 
was dark red (C).  Int. J. Med. Sci. 2011, 8 
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F i g u r e   6 GFP positive MSCs in different tissues after intravenous transplantation under fluorescence microscope.   a: Lung; b:  
L i v e r ;   c: bone marrow; d: normal femoral head; e: necrotic femora l   h e a d   a t   2   w   a f t e r   MSCs transplantation; f: necrotic femoral 
head at 4 w after MSCs transplantation; g:   n e c r o t i c   f e m o r a l   h e a d   a t   6   w   a f t e r   MSCs transplantation. Green cells were GFP 
positive MSCs.   F i g u r e s   a’-g’ were sections under light microscope.  
 
 
Table 1. Number o f   G F P -labeled MSCs in different tissues 
of rabbits at different time points (n=3) 
Tissues  2w  4w  6w 
Lungs  22.67±1.53  18.67±1.53  11.67±1.53 
Liver  26.67±1.53  19.67±1.53  13.33±1.53 
Bonemarrow  40.00±4.36  29.00±1.00  23.33±1.53 
Normal femoral head 12.67±1.53  9.67±0.58  6.33±0.58 
Necrotic femoral 
head 
26.33±0.58  49.33±2.52*#  66.33±3.51*# 
Note: * P<0.05 vs 2 w; # P<0.05 vs 2 w and 4 w. 
 
Discussion  
At present, intravenous transplantation has been 
a  common  strategy  in  the  stem  cell  transplantation 
and researchers have applied it in the treatment of a 
lot of diseases including severe autoimmune diseases 
(systemic  lupus  erythematosus,  multiple  sclerosis, 
rheumatoid  arthritis,  etc) [11-14], myocardial infarc-
tion [15-17], liver failure [18], trauma [19-21]. Recent-
l y ,   i n   o r d e r   t o   i m p r o v e   t h e   efficacy o f   s t e m   c e l l   t r a n s-
plantation, committed stem cells are isolated and pu-
rified,  and  single lineage stem cell transplantation is 
then performed.   D e n g   e t   a l   applied intravenous infu-
sion of MSCs in the treatment of spinal cord injury [6]. 
Lange et al treated  the  a c u t e   r e n a l   f a i l u r e   b y   i n t r a-
venous infusion of MSCs [7].  
Ischemic  necrosis  is  the  most  common  type  of 
femoral head necrosis. Ischemic femoral head necrosis 
refers to a disease which results from interruption of 
blood supply to the f e m o r a l   h e a d   r e s u l t i n g   i n   i s c h e-
m i a ,   n e c r o s i s   a n d   c o l l a p s e   o f   f e m o r a l   h e a d .   T h i s   d i s-Int. J. Med. Sci. 2011, 8 
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ease  is  frequently  found  in  middle-aged  adults  and 
leads to serous hip joint dysfunction. Ischemic femor-
a l   h e a d   n e c r o s i s   h a s   b e e n   o n e   o f   c o m m o n   b u t   r e f r a c-
tory diseases. The clinical treatments of ischemic fe-
moral  head  necrosis  include:  (1)  Non-surgical treat-
ments  [22-24]:  pharmacotherapy,  extracorporeal 
shock  wave  therapy,  hyperbaric  oxygen,  interven-
tional  therapy,   e t c .   T h e   e f f i c a c y   o f   non-surgical 
treatments is uncertain and different strategies have 
distinct  efficacy.  With  the  development  of  imaging 
technique, molecular biology technique and  physical 
therapy,  great  progress  has  been  made  in  the 
non-surgical  treatments  ischemic  femoral  head  ne-
crosis.  (2)  Palliative  surgery  [25-29]:  bone  grafting, 
vascular grafting, sequestrum removal+bone tampo-
nade, core decompression surgery, etc. The efficacy of 
these strategies is inconsistent and they have disad-
vantages of difficult manipulation. In addition, sur-
g e r y   m a y   c a u s e   n e w   t r a u m a   a n d   i n c r e a s e   t h e   t h e r a-
peutic  cost.  (3)  arthroplasty  [30,31]:  Currently,  the 
efficacy  of  arthroplasty  has  been  significantly  im-
proved. However, nowadays, a lot of younger adults 
develop ischemic femoral head necrosis, and lifetime 
of prosthesis, risk of surgery and high cost for surgery 
limit its application in a majority of patients. The ab-
ovementioned strategies have limitations and thus it 
is imperative to develop non-invasive or minimally 
invasive  strategies  with  high  therapeutic  efficacy. 
Recently, the progress in the therapeutic application 
o f   s t e m   c e l l s   p r o v i d e s   p r o m i s e   f o r   t h e   t r e a tment  of 
ischemic femoral head necrosis. When compared with 
vascular intervention and  local drilling for injection, 
transplantation with stem cells has advantages of mi-
nimally invasive and simple manipulation. Therefore, 
in recent years, a lot of physicians apply stem cell 
transplantation  in  the  treatment  of  femoral  necrosis 
[32-37].   H o w e v e r ,   i n t r a v e n o u s   i n j e c t i o n   o f   s t e m   c e l l s  
as  a  therapeutic  strategy  is  less  investigated  in  the 
treatment of femoral head necrosis.  
Safety is a critical concern of intravenous trans-
plantation of MSCs. Whether intravenous transplan-
tation  of  MSCs  can  cause  immunological  rejection? 
S t u d i e s   o n   t h e   i m m u n o g e n i c i t y   o f   b o n e   m a r r o w   M S C s 
reveal that MSCs can not only avoid the immunolog-
ical rejection in autologous transplantation, but also 
reduce  the  immunological  rejection  in  allogeneic 
transplantation by inhibiting cell proliferation. Laza-
r u s   e t   a l   i n t r a v e n o u s l y   i n j e c t e d   b o n e   m a r r o w   M S C s of 
different  concentrations  into  volunteers,  and results 
showed transplantation of even up to 5×107 MSCs did 
not  cause  obvious  immunological  rejection  [38]. 
Moreover,  MSCs  can also  regulate  the  secretion  of 
TNF-α ,   I F N -α ,   I L -4, and IL-10 and modulate Treg cells 
to reduce the incidence of graft-versus-host disease.   I n  
addition, inhibition or restriction of these  inflamma-
tory mediators also alleviates further damage to the 
bone, cartilage and blood supply to  necrotic femoral 
head [39]. Liu et al conducted a phase I clinical trial to 
evaluate  the  feasibility  and  safety  of  intravenous 
transplantation  of  stem  cells.   I n   t h e i r   s t u d y ,   MSCs 
were  isolated  from  rhesus  monkey  and  humans  in 
vitro[40].  The purified MSCs   o f   p a s s a g e   3   were  in-
jected into rhesus monkeys and volunteers, indepen-
dently.   D u r i n g   t h e   i n j e c t i o n ,   t h e   v i t a l   s i g n s   w e r e  
normal.  Before  and  after  injection,  the  subjects  re-
ceived routine blood examination, routine bone mar-
row  examination,  examinations  of  liver  and  renal 
functions  and  lymphocyte  subset.  Their  results  re-
vealed that intravenous transplantation of MSCs was 
s a f e   a n d   f easible. Devine et al intravenously injected 
autologous and allogeneic MSC into baboons, and no 
toxic reactions were observed during 1-year follow-up 
[41].  Another  intravenously  injected  allogeneic  ma-
caque  MSCs  i n t o   m a c a q u e s   o r   M S C s  were  directly 
injected into bone marrow [42].  No abnormalities in 
r o u t i n e   b l o o d   e x a m i n a t i o n   a n d   l i v e r   a n d   r e n a l   f u n c-
tions,  no  manifestations  of  acute  and  chronic  toxic 
reactions and graft versus host disease, no local swel-
ling at injection sites, and  no  lower limb  movement 
disorder were found during the 2-month follow-up. 
Nevertheless,  the  safety  of  intravenously  implanted 
allogeneic MSCs with high purity should be further 
confirmed. In the present study, no local or systematic 
manifestations  of  acute  and  chronic  toxic  reactions 
a n d   g r a f t   v e r s u s   h o s t   d i s e a s e   w e r e   o b s e r v e d   d u r i n g  
and after MSC transplantation. Meanwhile, the body 
temperature, routine blood parameters and liver and 
renal  functions  were  shown  normal. These  findings 
demonstrate that intravenous transplantation of allo-
geneic MSCs with high purity is feasible and safe.  
Another concern of intravenous transplantation 
of MSCs is whether the MSCs can migrate  into and 
proliferate in  the target tissues, w h i c h   i s   t h e   b a s i s   o f  
therapeutic effects of MSCs. In  adults,  MSCs remain 
the  potentials  of  multi-directional  and  mul-
ti-functional differentiation, and MSCs mainly exist in 
"storage  pool"  such  as  bone  marrow,  periosteum, 
b l o o d   v e s s e l s   a n d   l o o s e   c o n n e c t i v e   t i s s u e ,   a n d   p l a y  
important roles in the repair following tissue injury. 
MSCs may be motivated to participate in the repair of 
injured  tissues  through  blood  circulation  especially 
after  ischemia,  trauma,  and  irradiation  [43-46].  At 
present, it is recognized that the stem cell homing is 
executed in two ways:   ( 1 )   C e l l   n e c r o s i s   after trauma 
induces the release of a series of signal molecules, and 
stem cells are  motivated and migrate into peripheral 
blood and target tissue, in which specific receptors or 
ligands  expressed  in  injured  tissues  play important Int. J. Med. Sci. 2011, 8 
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roles. (2) Stem cells circulate among tissues, and stem 
cells migrate to the injured tissues once injury occurs. 
Stem cell homing is a complicated process in which a 
lot  of  molecules  were  involved.  Once  tissues  were 
ischemic, stem cells in circulation are adherent to the 
vascular endothelial cells, cross the endothelial cells, 
migrate  and  finally  reached  at  ischemic  sites.  In-
flammatory  may  be  observed  in  the  local  ischemic 
tissues, and thus a lot of chemotatic factors including 
interleukin-8  (IL-8),  monocyte  chemoattractant  pro-
tein  (MCP-1), stromal cell-derived factor (SDF-1) and 
tumor  necrosis  factor  (TNF)  are  produced.  Mean-
while, the expressions of a variety of adhesion mole-
cules  are  also  up-regulated  in  vascular  endothelial 
cells  [47].  These  changes  in  the  micro-environment 
may  contribute  to  the  s t e m   c e l l   h o m i n g ,   w h i c h   i s  
named  by  Helmuth  et  al  [48]   a s   “ t h e   c a l l   o f   i n j u r e d  
t i s s u e s   f o r   s t e m   c e l l s ” .   S i m i l a r l y ,   i n   o r d e r   t o   c o n f i r m  
that  intravenously  implanted  allogeneic  MSCs  can 
m i g r a t e   t o   t h e   f e m o r a l   h e a d ,   t w o   experiments were 
carried  in  this  study.  First, the  distribution  of  allo-
geneic  MSCs  in living nude mice was  dynamically 
monitored after MSC injection. Results showed MSCs 
can not only migrate into the femoral head, but also 
retain in the femoral head for a relatively long  time. 
Second, the sections of bone marrow, lungs, liver, and 
normal  and  necrotic  femoral  heads  of  rabbits  with 
MSC  transplantation  were  observed  under  fluores-
cence  and  light  microscope.  Results  revealed  the 
amount  of  MSCs  in  the  necrotic  femoral  head  was 
higher than that in the normal femoral head, liver and 
lungs,  indicating  that  femoral  head  ischemia  or ne-
crosis can call MSCs to  migrate  into  and  survive in 
injured femoral heads. The above-mentioned findings 
provided evidence on the curative effects of allogeneic 
MSC  transplantation  on  ischemic  femoral  head  ne-
crosis. 
In the intravenous transplantation of stem cells, 
i t   i s   v e r y   i m p o r t a n t   t o   o b s e r v e   t h e   s u r v i v a l   a n d   c u r a-
tive  effects  of  transplanted  stem  cells.  Traditional 
immunohistochemical method can easily identify the 
transplanted cells with specific morphology and tis-
sue-specific antigens. However, transplanted MSCs in 
t a r g e t e d   t i s s u e s   p r e s e n t   n o r m a l   c e l l   m o r p h o l o g y   a n d  
may be absent of specific markers. Thus it is difficult 
to determine the implanted allogeneic cells at injured 
sites.  Therefore,  cells  should be  labeled in vitro.  An 
ideal labeling method in vitro must possess high sen-
sitivity and specificity, and long half-life. At present, 
there  a r e   a   l o t   o f   l a b e l i n g   m e t h o d s   including  GFP 
labeling, Lacz labeling, BrdU labeling, Y chromosome 
labeling and  DiI  labeling. GFP protein is stable. GFP 
gene can  be transfected into MSCs through adenovi-
rus  vector,  resulting  in  stable  GFP  expression  in 
MSCs. Although the half-life of GFP is relatively short 
(4-6   w e e k s ) ,   i t   i s   e n o u g h   t o   t r a c e   t h e   m i g r a t i o n  of im-
planted cells during the process of bone formation.  
Although our results showed intravenously  im-
planted allogeneic MSCs could directionally migrate 
to femoral heads, and survive  especially in  the  ne-
crotic femoral heads, the mechanisms underlying the 
directional migration of MSCs s h o u l d   b e   f u r t h e r   s t u-
died. Besides, the efficacy of intravenous transplanta-
tion  of  MSCs  in  the  treatment  of  ischemic  femoral 
head necrosis should also be further confirmed. 
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